Clinical reasoning
Doxorubicin is an anthracycline that can transiently discolor urine red or pink because the drug itself and its metabolites are reddish. However, that discoloration appears within
1–2 days after the infusion and clears quickly. In this patient, pink urine began
6 days after doxorubicin plus cyclophosphamide, and it is accompanied by
dysuria and
urinary frequency. The timing and symptoms point away from harmless drug-related color change and toward bladder mucosal injury or infection.
Cyclophosphamide is metabolized to acrolein, a urotoxic metabolite that directly irritates the bladder mucosa and can cause hemorrhagic cystitis. The risk rises when urine output is low because the metabolite remains concentrated in the bladder for longer. This patient has been drinking only about
1 liter of fluid daily, which is inadequate for high-dose or moderate-dose cyclophosphamide therapy. The burning and frequency suggest chemical irritation, while the pink urine suggests microscopic or macroscopic bleeding from inflamed bladder mucosa. Infection must also be considered, but the absence of fever does not rule out cystitis.
Watch out! Do not dismiss pink urine as “normal doxorubicin color” when it starts days after the infusion or when voiding symptoms are present. That pattern requires prompt assessment.
Nursing priority
The correct action is to
report the symptoms for prompt review and
increase fluid intake. Generous hydration dilutes acrolein and other irritating metabolites, reduces their contact time with the bladder wall, and promotes frequent bladder emptying. In a chemotherapy day unit, this patient may need urinalysis, urine culture, assessment of renal function, and possibly mesna or other supportive measures depending on the clinical picture.
A fluid intake of about 1 liter per day is insufficient for a patient receiving cyclophosphamide; the goal is usually 2–3 liters per day unless a comorbidity such as heart failure or renal impairment restricts fluids. Frequent voiding is also important because prolonged retention of concentrated urine worsens mucosal exposure.
| Assessment finding | Likely interpretation | Nursing implication |
|---|
| Pink urine 6 days after doxorubicin | Not typical doxorubicin discoloration, which occurs within 1–2 days | Evaluate for bladder bleeding or infection |
| Burning and frequency | Bladder mucosal irritation or cystitis | Obtain urine specimen; report promptly |
| Fluid intake about 1 L/day | Concentrated urotoxic metabolites after cyclophosphamide | Increase fluids to dilute acrolein |
| No fever | Does not exclude hemorrhagic cystitis or early infection | Do not use absence of fever to delay evaluation |
Why the other options are less appropriate
Advising cranberry juice and waiting until the next cycle delays needed evaluation of possible hemorrhagic cystitis or infection. Cranberry juice is not a treatment for cyclophosphamide-induced bladder injury and may worsen bladder irritation in some patients. Advising less fluid would increase the concentration of urotoxic metabolites and worsen mucosal damage. Explaining that doxorubicin normally turns urine red is only accurate for the first
1–2 days after administration, not for new symptoms on day
6.
Link to supportive care principles
Chemotherapy-related toxicities can impair quality of life when they are not anticipated and managed early. Myelosuppression is one major concern, but non-hematologic toxicities such as hemorrhagic cystitis also require proactive nursing surveillance. In this case, the priority is to recognize that the timing and character of the urine change do not match a benign drug-color effect.
Early recognition of cyclophosphamide-induced bladder irritation allows interventions such as increased hydration, frequent voiding, and possible mesna administration before severe bleeding develops.
Key point! Pink urine with dysuria and frequency starting several days after cyclophosphamide is a warning sign for hemorrhagic cystitis or infection, not a normal doxorubicin effect. The first nursing actions are prompt reporting and increased fluid intake to dilute urotoxic metabolites.